Literature DB >> 18479738

Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation.

Ji-Weon Seo1, Hyun Kyung Kim, Ji-Eun Kim, Seonyang Park, Han-Ik Cho.   

Abstract

BACKGROUND: Widespread coagulation activation and intravascular fibrin formation are clinical features of disseminated intravascular coagulation (DIC). The endogenous thrombin potential (ETP) has been shown to be a useful marker for hypo- or hypercoagulability. The factor Xa-activated clotting time (XACT) represents plasma levels of procoagulant phospholipids. We investigated whether the ETP and XACT would be good prognostic markers in patients suspected of having DIC and whether these markers would show a significant correlation with the thrombin-antithrombin complex (TAT), a marker of in vivo coagulation activation.
METHODS: One hundred twenty-nine patients suspected of having DIC were enrolled for the study. The TAT was measured by ELISA. The ETP and XACT were measured by calibrated automated thrombinography. The 28-day mortality was used as a predictor of clinical outcomes.
RESULTS: In overt DIC, higher XACT (9.67 vs. 7.33 min) and higher TAT (26.15 vs. 11.56 ng/ml) results were obtained from the nonsurvivors than from the survivors. ETP levels were lower in the overt DIC group than in the no overt DIC group. In receiver operating characteristic analysis, which was conducted to predict the 28-day mortality, the areas under the receiver operating characteristic analysis curve were as follows: 0.71 (95% CI: 0.62-0.78) for the XACT, 0.70 (0.61-0.77) for the TAT, and 0.64 (0.55-0.72) for the ETP. For the diagnosis of overt DIC, the area under the curve of XACT, TAT and ETP were 0.77 (0.69-0.84), 0.64 (0.55-0.72) and 0.73 (0.64-0.80), respectively. The odds ratio of the XACT for the relative risk of 28-day mortality was 9.60 (3.53-26.11), and that of the TAT was 5.18 (2.11-12.72) and that of the ETP 7.66 (1.67-35.17). For the diagnosis of overt DIC, the odds ratio of XACT, TAT and ETP were 37.35 (4.86-286.89), 4.89 (1.93-12.43) and 4.89 (1.98-12.09), respectively. There was a negative correlation between the TAT and ETP (r=-0.223, P=0.012) and a positive correlation between the TAT and XACT (r=0.251, P=0.004).
CONCLUSION: Our results suggest that the XACT and ETP may be useful diagnostic and prognostic markers for the DIC. Among various markers, the XACT serves as a good prediction of the 28-day mortality in patients suspected of having DIC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18479738     DOI: 10.1016/j.thromres.2008.03.017

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Diagnostic and Prognostic Value of Plasma Factor V Activity and Parameters in Thrombin Generation for Disseminated Intravascular Coagulation in Patients with Hematological Malignancies.

Authors:  Hai-Ming Kou; Xiao-Ping Zhang; Man-Zhi Wang; Jun Deng; Heng Mei; Yu Hu
Journal:  Curr Med Sci       Date:  2019-07-25

2.  Activation of the Intrinsic Coagulation Pathway in Patients With Chronic Urticaria.

Authors:  Jung Ah Kim; Sujeoung Kim; Ji Eun Kim; Ja Yoon Gu; Hyun Ju Yoo; Hye Ryun Kang; Hyun Kyung Kim
Journal:  Allergy Asthma Immunol Res       Date:  2015-05-22       Impact factor: 5.764

3.  Role of a thrombin generation assay in the prediction of infection severity.

Authors:  Boaz Elad; Gilat Avraham; Naama Schwartz; Adi Elias; Mazen Elias
Journal:  Sci Rep       Date:  2021-04-09       Impact factor: 4.379

4.  Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.

Authors:  Heleen M Oudemans-van Straaten; Muriel van Schilfgaarde; Pascal J Molenaar; Jos Pj Wester; Anja Leyte
Journal:  Crit Care       Date:  2009-12-03       Impact factor: 9.097

5.  Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19.

Authors:  Marco G Mennuni; Roberta Rolla; Leonardo Grisafi; Enrico G Spinoni; Andrea Rognoni; Veronica Lio; Luigi M Castello; Pier P Sainaghi; Mario Pirisi; Gian Carlo Avanzi; Marco Krengli; Mattia Bellan; Daniela Ferrante; Gianluca Aimaretti; Umberto Dianzani; Giuseppe Patti
Journal:  J Thromb Thrombolysis       Date:  2021-06-10       Impact factor: 2.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.